CN118159543A - 在治疗细菌感染中使用的咪唑并吡啶酰胺和相关化合物 - Google Patents

在治疗细菌感染中使用的咪唑并吡啶酰胺和相关化合物 Download PDF

Info

Publication number
CN118159543A
CN118159543A CN202280072326.8A CN202280072326A CN118159543A CN 118159543 A CN118159543 A CN 118159543A CN 202280072326 A CN202280072326 A CN 202280072326A CN 118159543 A CN118159543 A CN 118159543A
Authority
CN
China
Prior art keywords
mmol
alkyl
synthesis
mixture
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280072326.8A
Other languages
English (en)
Chinese (zh)
Inventor
J·M·巴托洛梅-涅夫雷达
M·L·马丁-马丁
D·A·兰普雷希特
B·H·T·斯图普斯
K·I·E·阿姆索姆斯
G·A·F·维尼斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen R&D Ireland ULC
Original Assignee
Janssen R&D Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R&D Ireland ULC filed Critical Janssen R&D Ireland ULC
Publication of CN118159543A publication Critical patent/CN118159543A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202280072326.8A 2021-10-28 2022-10-27 在治疗细菌感染中使用的咪唑并吡啶酰胺和相关化合物 Pending CN118159543A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21205213.8 2021-10-28
EP21205213 2021-10-28
PCT/EP2022/080058 WO2023073090A1 (en) 2021-10-28 2022-10-27 Imidazopyridine amides and related compounds for use in the treatment of bacterial infections

Publications (1)

Publication Number Publication Date
CN118159543A true CN118159543A (zh) 2024-06-07

Family

ID=78414322

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280072326.8A Pending CN118159543A (zh) 2021-10-28 2022-10-27 在治疗细菌感染中使用的咪唑并吡啶酰胺和相关化合物

Country Status (11)

Country Link
US (1) US20250034171A1 (enExample)
EP (1) EP4423097A1 (enExample)
JP (1) JP2024540052A (enExample)
KR (1) KR20240090864A (enExample)
CN (1) CN118159543A (enExample)
AR (1) AR127483A1 (enExample)
AU (1) AU2022377203A1 (enExample)
CA (1) CA3234515A1 (enExample)
IL (1) IL312366A (enExample)
TW (1) TW202325274A (enExample)
WO (1) WO2023073090A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024089170A1 (en) * 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2024223859A1 (en) * 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
JP2026525955A (ja) 2023-07-18 2026-08-04 ヤンセン ファーマシューティカ エヌ．ベー． ベダキリン、プレトマニド又はデラマニド、及びシトクロムｂｃ１阻害剤を含む、少なくとも三種の抗生物質の組み合わせ製品、並びにマイコバクテリア感染症の治療におけるそれらの使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1527050T1 (sl) 2002-07-25 2010-08-31 Janssen Pharmaceutica Nv Kinolinski derivati in njihova uporaba kot mikobakterijski inhibitorji
RU2576662C2 (ru) 2010-03-18 2016-03-10 Энститю Пастер Корея Противоинфекционные соединения
US8569283B2 (en) 2011-09-01 2013-10-29 Valentina Molteni Compounds and compositions as c-Kit kinase inhibitors
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
JP6483610B2 (ja) 2012-07-18 2019-03-13 ユニバーシティ オブ ノートルダム デュ ラック ５，５−ヘテロ芳香族抗感染症化合物
WO2015014993A2 (en) 2013-08-02 2015-02-05 Institut Pasteur Korea Anti-infective compounds
CN105524058B (zh) * 2014-10-21 2018-03-27 广州艾格生物科技有限公司 吡唑并[1,5‑a]吡啶类化合物及其应用
MD3316969T2 (ro) 2015-07-02 2022-07-31 Janssen Sciences Ireland Unlimited Co Compuși antibacterieni
MA45377A (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Co Composés hétérocycliques en tant qu'agents antibacteriens
EP3472152A1 (en) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacte rials
CN114423758B (zh) 2019-09-13 2025-05-27 爱尔兰詹森科学公司 抗细菌化合物
CA3211592A1 (en) * 2021-03-17 2022-09-22 Jerome Emile Georges Guillemont Antibacterial compounds
MX2023010941A (es) * 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.

Also Published As

Publication number Publication date
IL312366A (en) 2024-06-01
KR20240090864A (ko) 2024-06-21
TW202325274A (zh) 2023-07-01
AU2022377203A1 (en) 2024-06-13
EP4423097A1 (en) 2024-09-04
US20250034171A1 (en) 2025-01-30
AR127483A1 (es) 2024-01-31
JP2024540052A (ja) 2024-10-31
WO2023073090A1 (en) 2023-05-04
CA3234515A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
US12454533B2 (en) Fused ring derivative having MGAT-2 inhibitory activity
TWI806832B (zh) 作為異位shp2抑制劑之2,5-雙取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪
WO2025045233A1 (zh) 大环化合物及其制法和用途
WO2025051241A1 (zh) 大环化合物及其抗体-药物偶联物
WO2023030385A1 (zh) 嘧啶并环类化合物及其制法和用途
KR20240002245A (ko) Ras 저해용 조성물 및 방법
WO2021239058A1 (zh) 稠合三环类化合物、其药物组合物及用途
CN106573915B (zh) 针对布罗莫结构域有活性的化合物
CN109790146B (zh) 药物化合物
JP2022533260A (ja) タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用
TW201726606A (zh) 作為免疫調節劑之化合物
KR102106765B1 (ko) 폴리엔 마크로라이드 유도체
US10059705B2 (en) Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
TW201414737A (zh) 作爲激酶抑制劑之咪唑并三□甲腈
WO2021136354A1 (zh) 联苯类衍生物抑制剂、其制备方法和应用
WO2025167948A1 (zh) 嘧啶并大环类kras抑制剂
KR20240090864A (ko) 세균성 감염의 치료에 사용하기 위한 이미다조피리딘 아미드 및 관련 화합물
CN104592211A (zh) 联苯类化合物及其用途
TW202329950A (zh) 一種用於雄激素受體蛋白靶向降解的嵌合體化合物、其製備方法及其在醫藥上的應用
CN118076610A (zh) 具有ent1抑制活性的大环化合物
WO2021208918A1 (zh) 作为egfr抑制剂的三环化合物
CN114423758A (zh) 抗细菌化合物
CN115427394A (zh) 用于调节nr2f6的杂环化合物
WO2007020936A1 (ja) 抗真菌作用二環性複素環化合物
CN112135818A (zh) 4-羟基哌啶衍生物及其作为泛素特异性蛋白酶19(usp19)的抑制剂的用途

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40111960

Country of ref document: HK